Cytogenetic survey of 117 Tunisian patients with de novo myelodysplastic syndrome

Sendi, Halima Sennana; Hichri, Haifa; Elghezal, Hatem; Gribaa, Moez; Laatiri, Adnene; Elloumi, Moez; Lakhal, Raihane Ben; Sarkhosh, Ali

doi:10.1016/s0003-3995(02)01123-1

Cited by 2 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequencies of chromosomal abnormalities calculated from the all patients in each population by CC were shown in Figure 2. From this data, the frequency and pattern of chromosomal abnormalities were different in each population (Intragumtornchai et al, 1998;Sendi et al, 2002;Solé et al, 2005;Jung et al, 2011;Rashid et al, 2014;Elnahass and Youssif, 2018). From all of 50 patients in this study, the chromosomal abnormalities were found in 8.0% of the single, 2.0% of the double, and 6.0% of the complex karyotypes by CC.…”

Section: Discussionmentioning

confidence: 61%

Chromosomal Abnormalities in Myelodysplastic Syndrome Patients in Upper Northern Thailand

Phrommin

Tantiworawit

Rattanathammethee

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Chromosome detection is important in the diagnosis and prognosis of Myelodysplastic syndrome (MDS) patients. About 50% of MDS patients have chromosomal abnormalities. Moreover, chromosome 5 and 7 are common genetic abnormalities in MDS patients and use to identify prognosis risk group and the proper treatment in MDS patients. The objective of this study was to evaluate chromosomal abnormalities and clinical features of MDS patients in upper northern Thailand. Methods: Fifty bone marrow (BM) specimens were examined by conventional cytogenetic (CC) technique and fluorescence in situ hybridization (FISH) technique for detected chromosome 5 and 7 abnormalities. The clinical features were comparison between MDS patients with chromosomal abnormalities and those with normal karyotype. Results: Chromosomal abnormalities were detected in 8/50 MDS patients by CC and 17/50 cases by FISH technique. When the CC and FISH techniques were combined, chromosomal abnormalities increased to 21/50 cases. Abnormalities of isolated chromosome 5 were found in 13 cases and were associated with lower level of percentage blast of BM (p = 0.003) and higher level of hemoglobin (p = 0.019). Moreover, abnormalities of chromosome 7 were found in 3 cases, 1 case of isolated del(7q) and 2 cases of-7 and del(7q) with complex abnormalities. These three cases were associated with higher level of percentage blast of BM (p = 0.010). Conclusion: This study showed the frequency and pattern of chromosomal abnormalities of MDS patients in upper northern Thailand were different from other populations. MDS with isolated chromosome 5 abnormalities had clinical characteristics corresponding with patients in good prognosis risk group. However, MDS patients with chromosome 7 and complex abnormalities showed higher percentage blast of BM which high risk to progression to acute myeloid leukemia (AML). Combined CC and FISH techniques detect chromosomal abnormalities with greater frequency than when either technique is used alone.

show abstract

Section: Discussionmentioning

confidence: 61%

Chromosomal Abnormalities in Myelodysplastic Syndrome Patients in Upper Northern Thailand

Phrommin

Tantiworawit

Rattanathammethee

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…When we compared to the literature, along with the fact that our findings are similar, that the percentage increased to 75 percent in RAEB-2 cases can be explained with the low number of cases. In the study, which was made by Breccia et al [8], the transformation rates to AML was found to be 27% for RAEB-1 and 44% for RAEB-2. In the study, which was made by Kazuma et al [8], while the transformation of RAEB-1 to AML was 37.5% the transformation rate of RAEB-2 to AML was found to be 50%.…”

Section: Discussionmentioning

confidence: 91%

“…In the study, made by Halima et al, the chromosome 5q anomaly was found to be at the rate of 14%, monosomy 7 to be 7% and trisomy 8 to be 4% [7,8]. Again in our study, while 2 of the 8 cases, which subsequently transformed into AML, were found to have a normal cytogenetic structure, 1 of them to have a -Y and t (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) anomaly, 1 of them to have Del5q and t (1.7) anomaly, the remaining 4 cases' cytogenetic examination could not be determined due to insufficient metaphase. Because the number of cases is scarce and the cytogenetic examination of 4 cases could not be determined, a prognostic cytogenetic anomaly could not be found in terms of transformation to AML.…”

Section: Discussionmentioning

confidence: 93%

“…Again in this study, the average age was found to be 64.1. In another study that was made by Sendi et al [8], 117 MDS patients were examined, and the average age was found to be 58 and the ratio of men/women to be 1.7. In an 18-yearslong study that was made by Li et al [9], 351 MDS patients were examined, and the average age was found to be 45 and the ratio of men/women to be 2/1.…”

Section: Discussionmentioning

confidence: 96%

“…When we look at the literature, the cytogenetic anomaly incidence changes between 30 and 50% in the studies that were made on the MDS patients [8,11,12]. In the study, which was made by Romeo et al [7] with 40 people, the cytogenetic anomaly was determined to be at 35%, in the one, which was made by Sendi et al [8] with 117 people, at 55%, and in the one, which was made by Li et al [9] with 351 people, at 67.5%. When the relationship between the cytogenetic analysis results and gender, a significant relationship could not be found.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A retrospective evaluation of patients with myelodysplastic syndrome

Kaya¹,

Turğut

2019

j-ebr

View full text Add to dashboard Cite

To determine our results by examining patient's files who we followed up by myelodysplastic syndrome (MDS) diagnosis between 2005 and 2009 as retrospectively and to compare the accordance of our results with literature. Methods: We examined 55 patient's files who got MDS diagnosis in 4 year-term. Complete blood count, biochemical analysis, peripheral spread, bone marrow aspiration, bone marrow biopsy examinations, cytogenetic and fluorescence in situ hybridization (FISH) analyses were made for all cases. Results: Our patient's age average was 69 and when classified according to WHO criterion at the diagnosis time, % 13 (23,6) of cases got diagnosed with RA-RARS, % 29 (52,7) with RCMD-RS, %5 (9,1) with RAEB-1, % 4 (7.3) with RAEB-2, % 3 (5.5) with MDS 5q and % 1 (1.8) with secondary MDS. % 52 of the patients had normal cytogenetic structure. No relation was determined between patients' diagnosis and international prognostic scoring system (IPSS) scores. During the 4 year-term, our 13 patients died. 6 of these cases died by reason of transforming to acute myeloid leukemia (AML), and 7 patients died because of infection. Mean survival time of cases that died was 6 (1-7) months as of the diagnosis date. Whereas 8 cases were over 70 ages, 5 of our cases were under 70 ages. Conclusion: MDS is a disease that ranges between anemia and AML and requires cytogenetic trials for diagnosis along bone marrow aspiration and biopsy for the purpose of determining the treatment regimen and prognosis. Determining the IPSS scores of patients by obtained outcomes is required. Risk of transforming to acute leukemia and susceptibility to infection are important in terms of mortality. Overage of patient population restricts the treatment regimens. Age must be an important factor for prognosis and treatment choice.

show abstract

Cytogenetic survey of 117 Tunisian patients with de novo myelodysplastic syndrome

Cited by 2 publications

References 29 publications

Chromosomal Abnormalities in Myelodysplastic Syndrome Patients in Upper Northern Thailand

Chromosomal Abnormalities in Myelodysplastic Syndrome Patients in Upper Northern Thailand

A retrospective evaluation of patients with myelodysplastic syndrome

Contact Info

Product

Resources

About